All Stories

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two mid-stage trials of obeldesivir.

Jun 27, 2025 - 09:45
 0
Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials
Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two mid-stage trials of obeldesivir.
Read More

Tags:

Previous Article

Parfum : Givaudan s'empare du groupe brésilien Vollmens

Next Article

Opinion: Creating a better system to assess presidential physical and psychologi...

Related Posts

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

Gilead pays partner Hookipa $10M to take over HBV, HIV ...

May 22, 2025  0

Eli Lilly pays $1B upfront to buy gene editing partner Verve Therapeutics

Eli Lilly pays $1B upfront to buy gene editing partner ...

Jun 17, 2025  0

FDA clears Fujirebio's blood test for diagnosing Alzheimer's disease

FDA clears Fujirebio's blood test for diagnosing Alzhei...

May 16, 2025  0